Table 1 Basic clinical data
From: NK cell compartment in patients with coronary heart disease
CHD patients (n = 93) | Control group (n = 49) | p | |
|---|---|---|---|
Age (years)(median, 25th percentile/75th percentile) | 63, 57/69 | 64, 58/73 | 0,43 |
Men (%) | 56,99 | 42,86 | 0,11 |
Hypertension (%) | 79,78 | 10,20 | 0,0000 |
Diabetes (%) | 37,08 | 0 | - |
Stable angina (%) | 100 | - | |
Smokers (%) | |||
Current Ex-smokers Non-smokers | 15,19 56,96 27,85 | 10,53 39,47 50,00 | 0,03 |
NYHA, median, interquartile range | 0, 0–1 | - | - |
CCS, median, interquartile range | 2, 2–3 | - | - |
EuroSCORE, median, interquartile range | 3, 1–4 | - | - |
Medicines (%) | |||
β-blockers | 80,85 | 6 | 0,0000 |
Statins | 82,98 | 0 | - |
Ca – blockers | 18,08 | 4 | 0,45 |
Nitrates | 55,32 | 2 | 0,0000 |
Diuretics | 23,40 | 2 | 0,07 |
Spironolacton | 6,38 | 0 | - |
Insulin | 14,89 | 0 | - |
Oral anti-diabetics | 22,34 | 0 | - |
ASA | 91,49 | 0 | - |
Digoxin | 0 | 0 | - |
ACE inhibitors | 72,34 | 0 | - |